TLX

Telix Pharmaceuticals Limited (ASX:TLX) is a commercial-stage biopharmaceutical company founded in 2015 and headquartered in North Melbourne, Australia. The company recently went public on the NASDAQ in November 2024, marking a significant milestone in its growth trajectory. Telix specializes in developing and commercializing radiopharmaceuticals, which are radioactive drugs used for both diagnosing and treating cancer and rare diseases. The company has successfully transitioned from a development-stage biotech to a commercial enterprise, with its flagship product Illuccix already generating substantial revenue across multiple international markets including Australia, Belgium, Japan, Switzerland, and the United States.